Intervacc signs agreement for optimization of manufacturing

Intervacc is pleased to announce that an agreement has now been signed with PX´Therapeutics, Grenoble, France, for process optimization of Strangvac. PX´Therapeutics, a subsidiary of Aguettant pharmaceutical group, has the experience, facilities and personnel to...

Animal Pharm writes about strangles and Strangvac®

The recognized journal Animal Pharm once again highlights Strangvac® in an article about the research now approaching a solution regarding effective vaccine protection against strangles. The article points out that, despite over 100 years of research the disease...

Intervacc AB (publ) acquires Nordvacc

Stockholm, March 24, 2014 Press release Intervacc AB (publ) acquires Nordvacc Läkemedel AB and creates a leading player within the veterinary pharmaceutical market in Scandinavia and the Baltic countries. By the acquisition, Intervacc complements its on-going research...